Aspire-Lakewood Holdings, Inc.

AI-generated fair value estimate for this company.

Method: Cash-runway + pipeline-optionality model (no FCF DCF, pre-revenue): net cash = $12,167,136 cash minus $1,782,726 total liabilities (10-Q, period end 6/30/2026) = $10,384,410 divided by 1,402,557 shares (as of 8/7/2026) = $7.40/share net-cash floor; plus a judgment-based 25% option premium ($2.60M) for the lead OTASA sublingual-aspirin asset (NDA filing targeted year-end 2026), since no disclosed peak-sales/rNPV data exists to price it more precisely = $12.98M total divided by shares = $9.25/share

Reasoning: H1 2026 revenue was only $91,457 and operating cash burn was $5.15M (annualized approximately $10.3M), consistent with management's 'at least one year' runway guidance; standard FCF DCF is not meaningful for a pre-revenue biopharma, so value is anchored to net cash plus explicit, stated optionality for the single lead pipeline asset